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Abstract: Infectious diseases are one of the main causes of death all over the world, with antimicrobial resistance presenting a great challenge. New antibiotics need to be developed to provide
therapeutic treatment options, requiring novel drug targets to be identified and pursued. DNA topoisomerases control the topology of DNA via DNA cleavage–rejoining coupled to DNA strand passage.
The change in DNA topological features must be controlled in vital processes including DNA replication, transcription, and DNA repair. Type IIA topoisomerases are well established targets for
antibiotics. In this review, type IA topoisomerases in bacteria are discussed as potential targets for
new antibiotics. In certain bacterial pathogens, topoisomerase I is the only type IA topoisomerase
present, which makes it a valuable antibiotic target. This review will summarize recent attempts that
have been made to identify inhibitors of bacterial topoisomerase I as potential leads for antibiotics and
use of these inhibitors as molecular probes in cellular studies. Crystal structures of inhibitor–enzyme
complexes and more in-depth knowledge of their mechanisms of actions will help to establish the
structure–activity relationship of potential drug leads and develop potent and selective therapeutics
that can aid in combating the drug resistant bacterial infections that threaten public health.
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1. Introduction
Infectious diseases are diseases where certain microorganisms grow and replicate
inside a host, leading to damage or injury to body tissues of the host. Even normal flora
can cause diseases to the host if the host is immunocompromised, for instance in cancer
and acquired immunodeficiency syndrome (AIDS). Many effective antimicrobial agents
have been discovered and marketed so far. However, there has been a constant issue that
counteracts the effects of well-established antimicrobial agents, i.e., antimicrobial drug
resistance [1–3].
Antimicrobial resistance has been a major global health concern in recent years. Mechanisms of resistance vary [4,5], such as degrading or changing the drug molecule to an
inactive form inside the microorganism [6], modifying or protecting the target for the
antimicrobial agent by the microorganism [7,8], or pumping out the drug molecules from
the microorganism cell, known as efflux [9,10]. Resistance to antimicrobial agents is usually
genetically encoded by the microorganism, either on the bacterial chromosome, or on a
plasmid that can be spread among different strains of microorganisms, resulting in the
emergence of new resistant strains [11,12].
The number of deaths attributable to antimicrobial resistance is expected to continue
growing, hitting around 10 million cases in 2050 [13]. Worldwide, tuberculosis (TB) is
one of the top 10 causes of death. According to the WHO, TB is the leading cause of
death from a single infectious agent. TB caused an estimated 1.4 million deaths worldwide
in 2019, with an estimated 10.0 million new cases of TB, equivalent to 130 cases per
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100,000 population [14]. Globally, there were an estimated 558,000 new cases of rifampicinresistant TB (RR-TB). Among RR-TB cases, an estimated 82% were multidrug-resistant
TB (MDR-TB). Furthermore, 3.5% of new TB cases and 18% of previously treated cases
were MDR/RR-TB. Drug resistant TB is very difficult to treat [15]. Other examples of
drug resistant bacteria include the Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp. (ESKAPE)
pathogens [16,17].
Following the discovery of daptomycin in late 1980s [18], the process of novel antibiotic
discovery stagnated and could not keep up with the emergence of antibiotic resistant
pathogens [19,20]. Hence, the discovery of novel antimicrobial agents is an urgent need.
DNA topoisomerases are well known targets for antibacterial drug discovery [7,21–25].
Topoisomerases are responsible for controlling the topology of the genome, including local
and global DNA supercoiling [26,27]. DNA topology and topoisomerase functions play
important roles in replication, transcription, and genome stability [21,27–32].
In general, all DNA topoisomerases work by binding to the target DNA molecule,
cleaving one or both strands of the double helix, passing another single or double strand
through the break, and resealing the DNA [21,30]. A covalent complex is transiently formed
between an active tyrosine residue of the topoisomerase enzyme and one end of the broken
strand during the cleavage process. [33]. The covalent complex with cleaved DNA is a
vulnerable intermediate that can lead to cell death if trapped.
The interests in studying the structures, functions, mechanisms of actions, and inhibitors of DNA topoisomerases are mainly due to two reasons: (1) the pivotal role of
DNA topoisomerases in the management and control of DNA topology [21,30,32] and (2)
development of topoisomerase inhibitors into widely used clinical therapies for cancer
and bacterial infections [21,24,25,34–36]. Many efforts have been exerted so far to either
synthesize new molecules, or discover new bioactive molecules, which could potentially
inhibit specific members of the DNA topoisomerase family, to provide new treatment for
cancer and infectious diseases.
2. Type IA Topoisomerases
DNA topoisomerases are divided into two main categories: type I topoisomerases
and type II topoisomerases. Differences in DNA strand passage activity and catalysis are
the basis of this categorization, and each main category is subdivided into subcategories
according to the mode of DNA binding and relaxation. Type I topoisomerases break and
rejoin a single DNA strand during catalysis. On the other hand, type II topoisomerases
break and rejoin the two strands of a double helix in order to pass another intact double
helix through the break, promoting catenation/decatenation, unknotting/knotting, and
relaxation of positively and negatively supercoiled DNA [37]. Type II topoisomerases are
subcategorized into two subfamilies: topoisomerases IIA and topoisomerases IIB. All type
II topoisomerases covalently attach to the 50 end of the DNA through a phosphotyrosine
bond, requiring divalent magnesium cation and ATP hydrolysis. Archaeal and bacterial
type IIA topoisomerases, such as Escherichia coli DNA gyrase, are A2 B2 heterotetramers. In
contrast, eukaryotic type IIA topoisomerases are all homodimeric enzymes. The discovery
of topoisomerase VI, an A2 B2 heterotetrameric type II topoisomerase found in all archaea,
added a new type IIB subfamily to the type II topoisomerases. The relative arrangement of
elements required for type II topoisomerase’s mechanism as well as the overall structural
organization are dissimilar between the type IIA and type IIB topoisomerases [30]. Type
IIA topoisomerases cleave the opposing strands of duplex DNA with a four-base stagger,
while two-base staggered cuts are made by type IIB topoisomerases [37].
Type I topoisomerases are subcategorized into three subfamilies: topoisomerases
IA, topoisomerases IB, and topoisomerases IC [38]. Members of the topoisomerase IA
subfamily share common mechanistic features, such as being monomeric proteins and
covalent attachment to the cleaved DNA end through a 5’ phosphotyrosine bond. Divalent
cation is needed as a cofactor to complete the catalytic process. Finally, the members of this
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subfamily can relax negative supercoils because they only require single stranded regions
of the target DNA molecule for binding [39]. In the protein-mediated DNA gate model
for strand passage by type IA topoisomerases [40,41], a segment of single-stranded DNA
(ssDNA) binds through domains I and IV, and the active tyrosine residue in domain III
performs the nucleophilic attack on this G-strand ssDNA to create a break. Movement of
domains I and III away from each other results in gate opening (Figure 1) to allow passage
of another ssDNA strand (T-strand). Gate-opening dynamics of E. coli topoisomerase I and
III were observed recently in single-molecule studies [42]. The presence of Mg2+ divalent
ions is necessary for the process of DNA rejoining by type IA topoisomerases [43–45].
The divalent ion is hypothesized to help position the 30 -hydroxyl group of the cleaved
DNA in proximity to the phosphotyrosine linkage, where the 30 -hydroxyl group performs
a nucleophilic attack on the phosphotyrosine linkage leading to rejoining of the DNA
backbone [46]. The requirement for divalent ions and formation of 5-phosphotyrosine bond
are mechanistic similarities between type IA and type IIA topoisomerase. In contrast, type
IB and type IC topoisomerases do not require divalent ions for catalysis and are linked to
the 30 -phosphate in the covalent intermediate. There is no sequence or structural homology
between type IA, type IB and type IC topoisomerases [47]. Type IA topoisomerases are
the only family of topoisomerases that can catalyze topological changes on both DNA and
RNA molecules [48]. The activity of type IA topoisomerases is needed for overcoming
DNA or RNA topological barriers that require strand passage through the break mediated
by the topoisomerase IA on a single strand of nucleic acid [32,49]. At least one type IA
topoisomerase is present in all free-living organisms [50] found in the three kingdoms of life.
Drugs targeting bacterial or parasitic type IA topoisomerases for treatment of infectious
diseases must be selective in not inhibiting the human type IA topoisomerases TOP3A
and TOP3B.

Figure 1. DNA-gate formed by cleavage of G-strand DNA by type IA topoisomerase (A) Crystal structure of covalent
complex between single-stranded DNA (ssDNA) and E. coli topoisomerase I N-terminal domains I to IV (Protein Data Bank
(PDB) 3PX7). The active tyrosine residue Y319 is illustrated with the red color, and ssDNA is represented by the blue color.
(B) Gate opening and closing dynamics of bacterial topoisomerase IA. The enzyme is represented by the green shape and
the ssDNA is represented by the blue wavy line. The letter Y stands for the active site tyrosine residue Y319.
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2.1. Rationale for Type IA Topoisomerases as Drug Targets
Since topoisomerases play key roles in managing the topology of DNA, which, in
turn, is a major factor impacting cell viability, they have been widely targeted for clinical
treatment of cancer and infectious diseases [24,25,51]. Topoisomerase inhibitors can be classified based on the mechanism of action as poison inhibitors or catalytic inhibitors [52,53].
Poison inhibitors are agents that work by stabilizing the topoisomerase covalent complex
that is formed as an intermediate during catalysis, while catalytic inhibitors are agents
that work by interfering with the catalytic cycle of the enzyme in any other step, such
as inhibitors that prevent initial substrate binding or formation of the cleavage complex.
Topoisomerase targeting drugs in current clinical use are poison inhibitors against type IB
and type IIA topoisomerase [52–54]. Topoisomerase poison inhibitors cause loss of cellular
viability through accumulation of breaks in the chromosome, triggering apoptosis in cancer
cells [55] and oxidative damage cell death pathway in bacteria [56]. This mechanism of
cell death is highly efficient since it does not require the activity of most of the target
topoisomerase molecules to be blocked and the topoisomerase activity does not need
to be essential. Even though there are currently no approved drugs that utilize type IA
topoisomerases as cellular targets, it can be argued that since all topoisomerases utilize
an active site tyrosine to form the covalent intermediate, it should also be possible for a
poison inhibitor to trap the covalent complex formed by type IA topoisomerases.
2.2. Validation for Bacterial Topoisomerase IA as a Novel Antibiotics Target
Topoisomerase I and topoisomerase III are type IA topoisomerases that are present in
bacteria, with reverse gyrase being found in thermophilic bacteria. E. coli has both topoisomerase I and topoisomerase III present. Bacterial topoisomerase I is much more efficient
for relaxation of negatively supercoiled DNA during transcription while topoisomerase
III has a stronger decatenation activity for resolution of replication and recombination
intermediates [57–60]. Null mutation of topA in E. coli can be compensated by mutations
that reduce the activity of gyrase that has the opposite effect on DNA supercoiling [61–63].
Nevertheless, endogenous inhibitors of topoisomerase I activity including overexpressed
Tn5 transposase [64,65], T4 gp55.2 [66] and toxin YjhX [67] can inhibit cell growth and
result in a loss of viability. Furthermore, even though the essentiality of topoisomerase I in
some bacteria is uncertain, poison inhibitors against the type IA topoisomerase present in
every bacterium should generate bactericidal DNA lesions. The bactericidal consequence
of topoisomerase I covalent complex accumulation in E. coli was demonstrated through
identification of bacterial topoisomerase I mutants deficient in DNA rejoining [44,45,68–70].
The mutations involved include mutations in the conserved D111, D113 and E115 (DDE)
triad that bind Mg2+ required for DNA religation [69]. These dominant lethal topoisomerase I mutations mimic the expected action of type IA topoisomerase poison inhibitors.
It should also be noted that YjhX overexpression resulted in E. coli cell death, even though
YjhX has been shown not to be a poison inhibitor of E. coli topoisomerase I [67]. Therefore,
inhibitors of bacterial topoisomerase I do not necessarily have to act as topoisomerase
poisons to be bactericidal.
Studies have shown that topoisomerase I is essential for cellular viability of a number
of important bacterial pathogens, including Mycobacterium tuberculosis [71,72], Streptococcus
pneumoniae [73], P. aeruginosa [74] and Helicobacter pylori [75]. In bacteria that only have one
type IA topoisomerase, the catalytic activity of the enzyme should be essential for overcoming topological barriers that require passage of one strand of DNA through another single
strand [32], and catalytic inhibitors of topoisomerase I would have antibacterial efficacy regardless of the mechanism of topoisomerase inhibition. Hence, bacterial topoisomerase IA
represents a valid target for novel antibiotics aimed at overcoming antimicrobial resistance.
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2.3. Eukaryotic Type IA Topoisomerases as Potential Target for Infectious Disease Treatment
Fungi have only one type IA topoisomerase, TOP3, that has high degree of similarity
to bacterial topoisomerase III. The TOP3 mutant is not viable in Saccharomyces pombe [76,77]
and has a slow growth phenotype in Saccharomyces cerevisiae [78]. In higher eukaryotes, the
TOP3 gene has been duplicated into TOP3A and TOP3B isoforms [50]. TOP3A is essential
for mice embryo development [79]. TOP3B knockout mice developed to maturity but had
a shortened life span [80]. Human topoisomerase III beta (TOP3B) has been shown to have
both DNA and RNA topoisomerase activities [81,82]. It relaxes hyper-negatively supercoiled DNA in transcription and prevents R-loop accumulation [83,84]. Interaction between
TOP3B and mRNAs [85] is required for neurodevelopment and synapse formation [81,82].
Human TOP3B is stabilized by Tudor domain containing 3 protein (TDRD3) [84,86,87],
which was previously identified as a host protein needed for efficient replication of flaviviruses, such as dengue and yellow fever virus [88]. However, subsequent follow-up
studies on the role of TDRD3 in viral replication have revealed that TOP3B is the actual
host factor required for the efficient replication of all positive-sense single-stranded RNA
viruses, with TDRD3 playing a role in the stabilization of TOP3B [49]. Specific inhibitors
for TOP3B could potentially be useful as broad-spectrum antiviral treatments against
flaviviruses and coronaviruses including SARS COV-2 [49].
Topoisomerases in kinetoplastid parasites are potential targets for the development
of improved therapeutic options against deadly parasitic diseases [89,90]. Three type
IA topoisomerases are present in the kinetoplastids. In addition to functionally active
TOP3A [91] and TOP3B [92], a prokaryotic-like mitochondrial TOP1A is also present. The
mitochondrial TOP1A in Trypanosoma brucei is essential for late theta replication intermediates structure resolution [93]. Since the mitochondrial TOP1A has no close homologs in
humans, it could be a target for selectively toxic new antiprotozoal treatments [93].
3. Screening Approaches
3.1. In Silico Screening
Several strategies and techniques can be used to identify novel topoisomerase inhibitors for treatment of infectious diseases. A commonly used strategy is screening
chemical libraries composed of a large number of molecules for the desired activity. This
strategy has been widely used for decades in drug discovery. The chemical libraries used
could comprise of synthetic compounds, natural products, or both. In silico virtual screening employing docking and molecular dynamics (MD) simulations can be used first to
identify potential inhibitors from compound libraries, followed by biochemical assays on a
small number of in silico hits with the highest predicted binding affinity to confirm the interaction and assess the topoisomerase inhibition and antimicrobial activity. This approach
has been applied to identify inhibitors for E. coli and M. tuberculosis topoisomerase I using
either crystal structures or target structures generated by computational modeling [94–98].
3.2. Biochemical Screening Assays
Various biochemical assays can be used to assess the ability of a compound to inhibit
the activity of a specific topoisomerase, and to determine the mechanism of inhibition
so that the hit can be classified either as a catalytic inhibitor or as a poison inhibitor.
Examples include, but are not limited to, gel based-assays, fluorescence-based assays,
and detection of DNA-enzyme covalent complex via the rapid approach to DNA adduct
recovery (RADAR) assay.
Agarose gel electrophoresis can be used to determine the inhibition of the bacterial
topoisomerase I, since this enzyme relaxes supercoiled plasmid DNA. A supercoiled
plasmid DNA, representing inhibited enzyme or control reaction without enzyme, will
migrate the fastest, while the fully relaxed plasmid DNA will migrate the slowest in
an agarose gel electrophoresis experiment [99]. DNA can be visualized using ethidium
bromide staining. The presence of an effective inhibitor will prevent the enzyme from
relaxing the plasmid DNA, and it will instead remain supercoiled until the concentration
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of the inhibitor is sufficiently low for the enzyme to regain its activity. To further determine
the mode of inhibition, single-stranded DNA or oligonucleotide substrate labeled with
32 P at the 50 -end can be used to visualize the shortened cleavage product that results from
topoisomerase I cleaving the substrate following electrophoresis of the reaction products in
denaturing acrylamide gel [100]. A topoisomerase poison inhibitor is expected to result in
the increase in accumulated cleavage product.
Since gel electrophoresis is time consuming and low in throughput capacity, several
fluorescence-based assays have been developed to monitor topoisomerase activities and
detect potential inhibitors with high throughput capacity. One such assay involved the
use of an immobilized triplex-forming oligonucleotide capable of selectively capturing
supercoiled plasmids that can be quantified by SYBR Green dye [101]. Another group of
researchers have developed a homogenous assay that measures the fluorescence anisotropy
of the triplex-forming oligonucleotide and can be applied to assay the activity of both
E. coli gyrase and topoisomerase I [102]. A different approach is to insert into a plasmid
an inverted repeat containing a fluorophore-quencher pair that can emit fluorescence
depending on whether cruciform formation is facilitated by negative supercoiling of the
plasmid [103,104]. An assay based on supercoiling-dependent fluorescence quenching has
been used to study the kinetics of relaxation of negatively supercoiled DNA by E. coli and
Mycobacterium smegmatis topoisomerase I [105]. However, these fluorescence-based assays
designed for the measurement of supercoiling/relaxation of plasmid DNA have not yet
been applied to screen for bacterial topoisomerase I inhibitors from a large compound
library. An oligonucleotide substrate with fluorophore and quencher at the 50 and 30 ends
of the stem-loop structure was designed to detect the inhibition of DNA religation by
topoisomerase I poison inhibitors [106]. This assay identified organomercury compounds
that act as poison inhibitors against E. coli and Y. pestis topoisomerase I that bind Zn(II)
with cysteines [100].
The rapid approach to DNA adduct recovery (“RADAR”) assay was first developed
to purify and measure the level of topoisomerase–DNA complex trapped by anticancer
drugs that act as topoisomerase poison inhibitors in mammalian cells [107]. A modified
RADAR/ELISA assay can also measure the level of gyrase covalent complex trapped by fluoroquinolones in bacterial cells [108]. Recently, it has been shown that this RADAR/ELISA
assay can detect in E. coli and M. smegmatis increased accumulation of covalent complex
formed by bacterial topoisomerase I with mutations that inhibit DNA rejoining, providing a potential assay for the discovery and optimization of drugs that act as bacterial
topoisomerase I poison inhibitors [109].
4. Recent Attempts to Discover Novel Bacterial Topoisomerase I Inhibitors
During the past decade, various attempts have been made to find inhibitors of bacterial topoisomerase I to provide potential leads for the development of novel antibiotics,
aiming to combat antimicrobial resistance. These inhibitors are discussed below and the
half maximal inhibitory concentrations (IC50 s) for inhibition of E. coli or M. tuberculosis
topoisomerase I activity are shown in Table 1.
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Table 1. Recently described small molecule inhibitors of bacterial topoisomerase I activity.
Inhibitor

IC50
E. coli Topo I

IC50
M. tuberculosis Topo I

Bis-benzimidazole DPA 154 [110]
Bis-benzimidazole PPEF [111]
Imipramine [96]
Norclomipramine [96]
Polyamine 2471-12 [112]
Polyamine 2471-24 [112]
Gold(III) macrocycle 10 [113]
Gold(III) chelate 14 [113]
Fluoroquinophenoxazine 11a [114]
Fluoroquinophenoxazine 11g [114,115]
VCC891909 [98]
Seconeolitsine (SCN) [116]
N-methyl-seconeolitsine (N-SCN) [116]
Piperidine amide 7 [95]
NSC76027 [94]

6.6 µM
9.4 µM
No inhibition at 25 µM
No inhibition at 25 µM
7.5 µM
10 µM
5 µM
1.3 µM
0.48 µM
0.48 µM
n.d.
n.d.
n.d.
15.6–31.3 µM
2.2 µM

n.d. 1
n.d.
<0.1 µM
<0.1 µM
7.5 µM
7.5 µM
10 µM
1.3 µM
0.98 µM
0.24 µM
<7.5 µM
5.6 µM
8.4 µM
2 µM
4 µM

1

n.d.: Not determined.

4.1. Bis-Benzimidazoles
Bis-benzimidazole derivatives have gained much attention as potential therapeutics
since the development of Hoechst bis-benzimidazole 33,258 and 33,342 as DNA minor
groove binders that inhibit human topoisomerase I and show activity against certain
types of cancers [117,118], but the drug development efforts did not progress to clinical trials due to high cytotoxicity [119]. A series of bis-benzimidazoles with closely
related structures were synthesized by two different groups and found to provide selective inhibition of type IA E. coli topoisomerase I over inhibition of type IB human
topoisomerase I [110,120]. The bis-benzimidazoles specific for E. coli topoisomerase I exhibited low minimum inhibitory concentrations (MICs) of 8 µg/mL against bacterial
pathogens that included methicillin-resistant S. aureus (MRSA), vancomycin-resistant
Enterococcus faecalis, Staphylococcus epidermidis, A. baumannii, Shigella flexneri and clinical
isolates of E. coli [110,111,121]. However, most of these derivatives still had cytotoxicity concerns, due to their DNA-binding activity [110,121]. DPA 154, shown in Figure 2, was also
reported to elicit changes in the cellular ultrastructure including induction of spheroplasts
and membrane lysis, suggesting a dual mechanism of antibacterial action that includes
compromising cell membrane integrity [122]. In vivo efficacy against E. coli was demonstrated in the mouse systemic infection model as well as the mouse neutropenic thigh
model [111] for one of the bis-benzimidazoles, 20 -(4-ethoxyphenyl)-5-(4-propylpiperazin1-yl)-1H,10 H-2,50 -bibenzo[d]imidazole (PPEF), shown in Figure 2. It was proposed that
PPEF shifts the cleavage–religation equilibrium of E. coli topoisomerase I by binding to
the strictly conserved acidic triad D111, D113 and E115 (DDE) based on results from a
site-directed mutagenesis study [123] where the aspartate and glutamate residues in the
acidic triad were replaced with alanine residues. Circular dichroism studies and in silico
docking have shown reduced binding of PPEF to these mutants, especially for the double
mutants where two out of the three DDE residues were replaced by alanine [123]. This
acidic triad of bacterial topoisomerase I is known to be involved in interactions with Mg2+
ions [124,125]. Substitution of the first aspartate to asparagine has been shown to affect
metal binding and result in deficiency of DNA religation [69].
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Figure 2. Structures of bis-benzimidazoles Hoechst 33258, Hoechst 33342, 20 -(4-ethoxyphenyl)-5-(4propylpiperazin-1-yl)-1H,10 H-2,50 -bibenzo[d]imidazole (PPEF) and DPA 154.

4.2. Tricyclic Antidepressants
In silico docking was conducted to screen a library of FDA-approved drugs for their
potential activity against a homolog model of M. tuberculosis topoisomerase I with Mg2+
and a DNA fragment bound in the open state [96]. Clinically prescribed tricyclic antidepressant imipramine and norclomipramine, which is the active metabolite of another
tricyclic antidepressant (clomipramine), were then selected based on the docking results
for biochemical and whole cell assays. Imipramine and norclomipramine (Figure 3) were
found to inhibit M. tuberculosis topoisomerase I relaxation activity at <0.1 µM concentration following 15 min preincubation with the enzyme [96]. However, inhibition of E. coli
topoisomerase I was not detected at up to 25 µM compound concentration. In silico docking with the M. tuberculosis topoisomerase I homology model has placed imipramine and
norclomipramine near the strictly conserved DDE acidic triad. Alanine substitution at
the glutamate in the third position abolished inhibition by the compounds while alanine
substitution at the first aspartate had no effect on the inhibition. Both compounds showed
a slight increase in cleavage product from a 32 P-labeled double stranded oligonucleotide
substrate and enhanced cytotoxicity in M. smegmatis overexpressing recombinant mycobacterial topoisomerase I, consistent with the compounds acting with a poison inhibitor
mechanism [96]. However, the MICs required to stop the growth of M. tuberculosis were
relatively high (60 µM for norclomipramine and 250 µM for imipramine). The tricyclic antidepressants have hard-to-tolerate side effects and several drug–drug interactions, which
have recently led to the clinical preference of other classes of antidepressants [126]. Therefore, the tricyclic antidepressants are probably not a practical clinical option for targeting
bacterial topoisomerase I.
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Figure 3. Structures of tricyclic antidepressant imipramine and metabolite norclomipramine.

4.3. Inhibitors Based on Polyamine Scaffold
The collection of small molecules at Torrey Pines Institute (TPI) now consists of more
than 80 million small molecules organized into a small number of scaffold-ranking libraries
so that promising molecular scaffolds can be identified quickly from a positive result in a
biological assay. Structural analogs in the selected scaffold library mixtures can be studied
with position scanning to identify the most favorable substitutions in the specific molecular
scaffold [127–129]. This approach has been applied previously for the discovery of bacterial
tyrosine recombinase and site-specific recombinase inhibitors [130]. In efforts to discover
small molecules targeting bacterial topoisomerase I, inhibition of E. coli topoisomerase
I relaxation activity was assayed first to identify the most promising scaffold and then
the most inhibitory substitutions at three different R positions of the selected polyamine
scaffold (Figure 4A). Fourteen related compounds that were synthesized as part of the
2471 series based on the position scanning data showed IC50 values < 20 µM against E. coli
and M. tuberculosis topoisomerase I, and MIC values < 50 µM against M. smegmatis [112].
Among these 14 compounds, four polyamine analogues (Figure 4B) were confirmed to
be also active against M. tuberculosis with selectivity index (50% cytotoxic concentration
(CC50 ) against J774 macrophage cell line/IC50 against M. tuberculosis) values of up to
15. The observed inhibition of bacterial type IA topoisomerases by the 2471 compounds
is unlikely due to non-specific inhibition of the type IA topoisomerase activity by the
positively charged polyamine structure, or non-specific binding of the polyamine inhibitors
to DNA, as the IC50 values for inhibition of human topoisomerase IB and topoisomerase
II activities were >10 fold higher. Viable colony counts obtained following treatment of
M. smegmatis and M. tuberculosis showed that both MICs and cell killing efficacies of these
four polyamine analogs are sensitive to the level of topoisomerase IA activity. The bacteria
became less sensitive when recombinant M. tuberculosis topoisomerase I was overexpressed,
indicating catalytic inhibition of the topoisomerase IA activity as part of the antibacterial
mechanism of action. Further improvement of potency and selectivity is desirable for this
class of type IA topoisomerase inhibitors.
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Figure 4. (A) Polyamine scaffold and (B) individual polyamine inhibitors of bacterial topoisomerase I with antimycobacterial
activity [112].

4.4. Gold(III) Complexes
Metal-containing complexes have been used frequently as therapeutics throughout
history, such as the well-known anti-cancer drug cisplatin [131] and the gold-containing
auranofin used to treat rheumatoid arthritis [132]. Gold(III) tetra-aryl porphyrins with
anticancer activity were found to bind DNA and inhibit human topoisomerase I [133]. That
led to an increased interest in using gold compounds to inhibit topoisomerases. A number
of pyrrole-based gold(III) macrocycles were synthesized and tested for anticancer activity
and inhibition of human topoisomerase I [134]. The gold(III) macrocycle 10 illustrated in
Figure 5A was found to be a catalytic inhibitor of human topoisomerase I with selectivity
over human topoisomerase IIA. Gold(III) macrocycle 10 also caused lethality to many of the
NCI’s panel of 60 human cancer cell lines [134]. In a follow up study investigating potential
antibacterial application, some of the gold(III) macrocycles and additional bis(pyrrolideimine) gold(III) chelates were found to inhibit the growth of both M. tuberculosis and
Mycobacterium abscessus. The gold(III) chelate 14 (Figure 5B) showed a MIC of 1 µM against
M. tuberculosis and 10 µM against M. abscessus, with bactericidal activity against mycobacteria as well. Gold(III) macrocycle 10 had even lower MICs against the mycobacteria but
was not bactericidal, so these two compounds may have differences in their mechanism
of action. Gold(III) chelate 14 showed no activity against Gram-negative species and only
low level inhibition against other Gram-positives, suggesting that it has a specific activity
against mycobacteria, including fluoroquinolone-resistant strains [113]. Both compounds
shown in Figure 5 inhibit the relaxation activity of M. tuberculosis and E. coli topoisomerase
I (Table 1), without any effect on bacterial DNA gyrase activity, suggesting the specificity
these two compounds have for bacterial type IA topoisomerases inhibition [113]. Further
studies are required to characterize the mechanism of antimycobacterial action of these
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gold(III) compounds and provide more insights in their structure–activity relationship
(SAR) to limit the cytotoxicity.

Figure 5. Gold(III) inhibitors of bacterial topoisomerase I [113]. (A) Gold(III) macrocycle 10 and (B) gold(III) chelate 14.

4.5. Fluoroquinophenoxazine Derivatives
A fluoroquinophenoxazine NSC648059 was initially identified in enzyme-based screening of E. coli topoisomerase I inhibitors [114]. A series of fluoroquinophenoxazine derivatives were synthesized to evaluate the SAR and to probe the structural elements of the
fluoroquinophenoxazine core towards type IA topoisomerase target recognition. These
derivatives were assayed for selectivity in inhibition of type IA topoisomerases, and antibacterial activity. Comparative molecular field analysis (CoMFA) of the three-dimensional
quantitative structure–activity relationship (3D-QSAR) of these fluoroquinophenoxazine
derivatives resulted in a model with reasonable statistics (q2 = 0.688 and r2 = 0.806) and
predictive power (predictive correlation coefficient r2 pred = 0.767). While the structures of
these fluoroquinophenoxazines have similarities to fluoroquinolones that target bacterial
type IIA topoisomerases, this series of fluoroquinophenoxazines tested for selectivity exhibited much greater potency for inhibition of the type IA bacterial topoisomerase than
inhibition of E. coli gyrase, human type topoisomerase I and IIα [114]. Derivative 11a
with 6-methylpiperazinyl and 9-amino groups (Figure 6, IC50 = 0.48 µM) showed broad
spectrum antibacterial activity (MICs = 0.78–7.6 µM) against bacteria that include Gramnegative E. coli and M. tuberculosis. Derivative 11g with the 6-bipiperidinyl lipophilic
substitution showed the most promising antitubercular activity (MIC = 2.5 µM, selectivity
index (SI) = 9.8) and was also active (MIC = 50 µM) against a clinical isolate of Mycobacterium abscessus [114,115]. The mechanism of resistance in mycobacteria was investigated
by stepwise isolation of resistant mutants in M. smegmatis followed by comparison of the
whole-genome sequence of the original strain and mutant isolates. Mutations in genes that
affect compound entry and retention were identified instead of mutations in the topoisomerase I gene that might confirm the enzyme as the antibacterial target [115]. Biophysical
analysis showed that DNA binding by fluoroquinophenoxazine 11g may contribute to the
antibacterial mechanism, but could not account entirely for the direct binding and potent
inhibition of the mycobacterial topoisomerase I [115].
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Figure 6. Structures of fluoroquinophenoxazine 11a and 11g [114].

4.6. Vichem’s Benzo(g)quinoxaline Compound
Compounds with antitubercular activity were identified with whole-cell assays from
approximately 17,000 molecules in Vichem’s Nested Chemical Library (NCL) [135]. The
639 compounds with MIC values < 6 µM were assayed for inhibition of M. tuberculosis
topoisomerase I activity, and the results on the 108 compounds found to be active at 100 µM
were used for building machine learning models for M. tuberculosis topoisomerase I inhibitors [97]. A selected set of seven Vichem NCL molecules with benzo(g)-quinoxaline,
quinoxaline, or styryl-benzo(g)-quinazoline scaffolds was further characterized [98]. Cytotoxicity was measured against three human cell lines. In silico docking predicted strong
binding affinity to specific sites on M. tuberculosis topoisomerase I through interactions with
R167 and R114 [97,98]. The interaction of the selected hits with the human ATP-binding
cassette (ABC) multi-drug transporters was assessed for potential drug resistance. The
human ABCB (MDR/TAP) transporter family plays a major role in multiple drug resistance (MDR) against a variety of tuberculosis therapies, such as fluoroquinolones and
aminoglycosides [98]. Most of the hits demonstrated considerable interaction with the
transporters, except for VCC891909 (Figure 7). This compound also showed no cytotoxicity
in all the human cells lines tested in the cytotoxicity assays with efficient inhibition of
M. tuberculosis growth (MIC90 = 10.4 µM against H37Rv) and topoisomerase I activity
(complete inhibition at 7.5–10 µM), suggesting that VCC891909 might be a good candidate
for further antimycobacterial drug development [98].

Figure 7. VCC891909 from Vichem’s Nested Chemical Library (NCL) [98].

4.7. Alkaloids SCN and N-SCN
Two natural products and boldine-derivative alkaloids, seconeolitsine (SCN) and
N-methyl-seconeolitsine (N-SCN) (Figure 8), were previously found to inhibit both topoisomerase I activity and cell growth of Streptococcus pneumoniae at approximately 17 µM [136].
The targeting of topoisomerase I by these compounds was supported by evidence of hypernegative supercoiling of DNA in treated cells along with protection from overexpression of
topoisomerase I [136]. SCN has been used to demonstrate the homeostatic regulation of
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DNA supercoiling in S. pneumoniae by the topoisomerase I gene and the transcriptomic
response to changes in local and global supercoiling [137,138]. These two alkaloids were
tested more recently as potential inhibitors of M. tuberculosis topoisomerase I [116]. SCN
and N-SCN exhibited MIC values below 16 µM against multiple isolates of M. tuberculosis
and low IC50 values against the M. tuberculosis topoisomerase I (Table 1). SCN was shown
to inhibit the cleavage of a 50 -biotin-labeled 32-mer oligonucleotide by the enzyme. The
impact of N-SCN on DNA relaxation by topoisomerase I was confirmed by results from
the analysis of topoisomer distribution of the mycobacterial plasmid by two-dimensional
agarose gel, showing that the compound induced a 20% increase in plasmid supercoiling [116]. The action of both SCN and N-SCN as topoisomerase I catalytic inhibitors instead
of poison inhibitors I was further confirmed by the decreasing MIC values of both compounds against M. smegmatis strain that expresses decreased levels of topoisomerase I [116].
Partial inhibition of human topoisomerase I could be observed at 50 µM concentration
of SCN and N-SCN, with a small but significant effect on the viability of neutrophils at
100 µM concentration [136].

Figure 8. Alkaloids seconeolitsine (SCN) and N-methyl seconeolitsine (N-SCN) [136].

4.8. Additional Small Molecule Inhibitors Identified from Virtual Screening
Virtual screening was conducted sequentially to identify in silico hits against M.
tuberculosis topoisomerase I for assays of enzyme inhibition. The Asinex elite library of
104,000 compounds was first docked against the crystal structure (Protein Data Bank (PDB)
5D5H) of the truncated apo-enzyme of M. tuberculosis topoisomerase I, consisting of Nterminal domains D1–D4 plus C-terminal domain D5. The top 1000 hits were then docked
against 1000 structures of 5D5H generated by molecular-dynamics to allow deeper binding
of the molecules in the DNA-binding pockets. Six of the 82 in silico hits that were found
to show inhibition of M. tuberculosis topoisomerase I relaxation activity share a common
piperidine amide structural motif in the center that appears to interact with conserved R167
and E115 residues. Docking was then conducted for 200 compounds from the ChemBridge
library that have this piperidine amide motif. Among the 96 top-scoring ChemBridge
compounds purchased for testing, 18 compounds exhibited IC50 < 125 µM. Compound
seven (Figure 9) has the lowest IC50 (2 µM), and >250-fold selectivity over inhibition
of human topoisomerase I and E. coli gyrase. Antibacterial activity of the ChemBridge
hit compounds against M. smegmatis measured in the presence of efflux pump inhibitor
thioridazine showed higher MICs when M. tuberculosis topoisomerase I was overexpressed,
consistent with these compounds acting as catalytic inhibitors of topoisomerase I. Further
utilization of piperidine amide compounds for antimycobacterial activity would require
modifications that improve penetrance and retention of the compounds in mycobacteria.
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Figure 9. Bacterial topoisomerase I inhibitors identified by in silico screening—piperidine amide compound 7 [95] and
NSC76027 [94].

To identify candidates for bacterial topoisomerase I poison inhibitors, stabilization
of the covalent intermediate formed after DNA cleavage was targeted for in silico screening [94]. The C-terminal domains of E. coli topoisomerase I (from full length structure PDB
4RUL) were connected to the 67 kDa N-terminal domains in covalent complex with cleaved
DNA (PDB 3PX7) based on alignments of the two structures. CGenFF force field parameters
were applied to create the 50 -phospotyrosine linkage between the enzyme and cleaved
DNA, followed by the energy minimization of the structure. To demonstrate the utility
of this minimized E. coli topoisomerase I covalent complex model for in silico screening,
docking was conducted on 2263 molecules selected from the NCI DTP chemical library. Direct interaction between the enzyme and one of the top predicted hits (NSC76027, Figure 9)
was confirmed with surface plasmon resonance (dissociation constant KD = ~80 nM). The
IC50 value of NSC76027 against E. coli topoisomerase I was estimated to be 2.2 µM [94],
with a similar IC50 value of ~4 µM for inhibition of M. tuberculosis topoisomerase I relaxation activity (to be published), NSC76027 has no detectable antibacterial activity against
E. coli MG1655 but was found to inhibit growth of M. tuberculosis (MIC = 35 µM) [94].
Further experiments are needed to determine the mechanism of inhibition and selectivity
of NSC76027.
4.9. DNA Molecules as Bacterial Topoisomerase I Inhibitors
A distinct approach to target bacterial topoisomerase I is by using DNA molecules
as specific inhibitors. The first step in the catalytic cycle of the enzyme is the recognition
of the single-stranded regions in duplex DNA [139]. A series of 84 bp double-stranded
oligonucleotides with variations in the number of bulge bases in a single-stranded loop
were synthesized and tested for inhibition of the relaxation activity of E. coli topoisomerase
I [140]. Inhibition efficiency improves as the size of the single-stranded loop increases from
1 to 10 base in length with IC50 reaching 63.1 nM. Inhibition of eukaryotic calf thymus
topoisomerase I relaxation activity was not observed. It was hypothesized that because
the single-stranded loops in the bulge oligonucleotides are not base-paired, the bulge
oligonucleotides may be acting as irreversible competitive inhibitors [140].
In a second study, small circular DNA molecules with curvature that can be recognized
by bacterial topoisomerase I were also investigated as competitive catalytic inhibitors [141].
Several duplex small circular oligodeoxyribonucleotides (cODNs) of varying sizes were
designed, synthesized, and evaluated for inhibition of E. coli topoisomerase I relaxation
activity. The sizes of the DNA circles synthesized mattered because the degree of bending
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and torsional stress in the DNA molecule increases with decreasing ring size, and the
bending and torsional stress can be recognized by the enzyme. The biochemical evaluation
showed inhibition of DNA relaxation activity with a IC50 value of 36.4 nM for the 66 bp
cODN. Small single-stranded DNA circles or cODNs with seven base single-stranded
mismatches have even lower IC50 s (~10 nM) [141]. The cODNs have greater thermal
stability than the bulge oligonucleotides.
A general advantage of DNA molecules is the low toxicity for the host compared to
conventional drugs. The major drawback is that the ability of DNA molecules to penetrate
the bacterial cell wall is very low, so more advancements in drug delivery research is
needed [140,141].
5. Future Perspectives
Type IA topoisomerases are novel targets for infectious diseases for which no clinically approved drug has been developed so far. Effect of overexpression of the target
topoisomerase should be informative on the mechanism of inhibition, overexpression of
the target topoisomerase would increase the lethality of poison inhibitors. Conversely,
the increased level of the target topoisomerase would help to overcome the effect of the
catalytic inhibitors. The homeostatic regulation of bacterial topoisomerase I promoter
activity by DNA supercoiling could increase the level of topoisomerase I expression in
response to a catalytic inhibitor. The goal of finding and developing a successful drug
targeting this class of topoisomerases would be greatly facilitated by the availability of
the three-dimensional structure of topoisomerase–inhibitor complex, or ternary complex
with DNA also present. Identification of inhibitors with high binding affinity from specific
interactions with the topoisomerase protein residues would enable such structural studies.
The structural information on the molecular interactions between enzyme and inhibitor
would further validate the targeting of the type IA topoisomerase and allow structurebased design/optimization of type IA topoisomerase inhibitors for the development of a
new therapy in the fight against the antimicrobial resistance. Determining the structure of
a topoisomerase–RNA complex may also be useful for utilizing human TOP3B as a host
target for providing options of antiviral therapy during flaviviruses and the coronavirus
pandemics [49].
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Abbreviation
WHO
PDB
ELISA
MIC
CC50
IC50
FDA
NCI
SI
SAR

World Health Organization.
Protein Data Bank.
enzyme-linked immunosorbent assay.
minimum inhibitory concentration: The lowest concentration of an agent that stops microbial growth.
the 50% cytotoxic concentration: The concentration that reduces the cellular viability by 50%.
the half maximal inhibitory concentration: The concentration that reduces enzymatic activity by 50%.
Food and Drug Administration
National Cancer Institute
selectivity index: A ratio of cytotoxicity to antimicrobial activity.
structure–activity relationship: The relationship between the chemical structure of a molecule and its biological activities.
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3D-QSAR
CoMFA
CGenFF
DTP
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three-dimensional quantitative structure–activity relationship: A quantification of SAR via mathematical
relationships between physicochemical properties of a molecule and its biological activities.
comparative molecular field analysis: One of the QSAR methods, where mathematical relationships between steric
and electrostatic properties of a ligand and the resulting receptor–ligand interactions are determined.
CHARMM General Force Field
Developmental Therapeutics Program
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